Adult height has been positively associated with breast cancer risk. The timing of pubertal growth-as measured by age at menarche and age at attained height-may also influence risk. We evaluated associations of adult height, age at attained height, and age at menarche with incidence of invasive breast cancer in 55,687 African American women in the prospective Black Women's Health Study. Over 20 years, 1,826 invasive breast cancers [1,015 estrogen receptor (ER) positive; 542 ER negative] accrued. We used multivariable Cox proportional hazards regression to estimate hazards ratios (HRs) and 95% confidence intervals (CIs) for associations with breast cancer overall and by ER status, mutually adjusted for the three factors of interest. Adult height was associated with increased risk of ER1 breast cancer (HR for 70 inches vs 63 inches: 1.44; 95% CI: 1.09, 1.89) but not ER2 (corresponding HR: 1.16; 95% CI: 0.78, 1.71) (p heterogeneity 5 0.34). HRs for attained height before age 13 versus age >17 were 1.30 (95% CI: 0.96, 1.76) for ER1 and 1.25 (95% CI: 0.80, 1.96) for ER2 breast cancer. Results for age at menarche (11 vs 14 years) were similar for ER1 and ER2 breast cancer (HR for breast cancer overall: 1.30; 95% CI: 1.12, 1.50). We confirmed height as a strong risk factor for ER1 breast cancer in African American women and identified early age at attained height as a risk factor for both ER1 and ER2 breast cancer, albeit without statistical significance of the latter associations. While adult height and timing of pubertal growth are inter-related, our findings suggest that they may be independent risk factors for breast cancer.
It has been hypothesized that adolescence and young adulthood represent critical periods of breast cancer risk accumulation, 1 wherein the rapid proliferation of undifferentiated mammary cells confers increased vulnerability to hormonal and other carcinogenic influences. 2 Consistent evidence from epidemiologic studies shows that earlier age at menarche [3] [4] [5] [6] and taller adult stature are associated with increased risk of breast cancer. [7] [8] [9] [10] [11] These associations have been observed in both white 11 and black women. 6, 7, 12 Maximum adult height is determined by several factors, including genetics, 13 childhood and adolescent nutrition 14 and cumulative exposure to insulin-like growth factor 1 (IGF-1) and other growth hormones. 15, 16 IGF-1 levels are positively correlated with height in childhood [17] [18] [19] while taller height at any age during childhood has been associated with future risk of breast cancer. [20] [21] [22] In a large pooled study including >4,700 breast cancer cases, a positive association between circulating IGF-1 and breast cancer risk was observed. 23 This association could be explained, at least in part, by IGF-1 stimulation of mitosis and inhibition of apoptosis during pubertal breast development. 24, 25 Less well studied in relation to breast cancer risk are the timing and rate of pubertal growth. Rapid physical growth during puberty may have an important role in breast carcinogenesis. 26 Earlier onset of puberty is thought to reflect earlier exposure to IGF-1 and other growth hormones 15, 27 and a more intense period and/or longer duration of pubertal growth and higher peak height velocity. 28 Thus, pubertal growth patterns could explain the somewhat paradoxical findings that both earlier age at menarche and taller adult height-which are inversely associated with each other 22, [29] [30] [31] -are associated with increased risk of breast cancer. Age at attained height is directly correlated with age at peak growth, also known as the pubertal growth spurt. 32 Of six studies published to date that evaluated associations of age at attained height and breast cancer risk, 12, 27, [33] [34] [35] [36] all but one 34 reported inverse associations. Only one of these studies 12 evaluated associations separately by estrogen receptor (ER) status, but it was limited by small numbers of ER2 cases (n 5 78). Further, except for a preliminary report from the Black Women's Health Study (BWHS), published only in abstract form, 37 none of prior studies included sufficient separately. Given known differences in risk factor associations by hormone receptor subtype, 38 stronger associations of age at attained height with ER2 versus ER1 breast cancer observed in one previous study, 12 and the disproportionately high incidence of ER2 breast cancer in AA women, we sought to investigate the joint effects of maximum adult height, age at attained height, and age at menarche on ER2 and ER1 breast cancer risk among AA women in the prospective BWHS cohort.
Methods

Study population
The BWHS was established in 1995 with enrollment of 59,000 AA women aged 21-69 years (median age, 38 years). 39 At baseline, women provided information on their medical history as well as demographic, reproductive, lifestyle and early life factors via mailed self-administered questionnaires. Follow-up is ongoing and participants update information every 2 years. Notices of deaths are obtained from next-of-kin, the U.S. Postal Service, and yearly searches of the National Death Index. To date, follow-up of the baseline cohort has been successful for 87% of potential person-years. For this analysis, women were excluded if they had been diagnosed with breast cancer (n 5 767) or any other type of cancer (except nonmelanoma skin cancer) (n 5 531) before baseline in 1995 as well as if they were missing information on height, age at menarche, or body mass index at age 18 (n 5 1,303) or reported age at attained height as earlier than age at menarche (n 5 704); the final analytic cohort included 55,687 AA women aged 21-69 at baseline. The study protocol was approved by the Boston University Institutional Review Board.
Case ascertainment
Incident cases of invasive breast cancer in the BWHS were ascertained through self-report on biennial follow-up questionnaires (95% of cases) or identified through death records and linkage to 24 cancer registries in states covering 95% of participants (5% of cases). Diagnoses were confirmed by review of medical records, pathology reports and cancer registry records. Data on tumor characteristics were also abstracted from these records. Of cases for which pathology records have been received to date (>80%), >99% were confirmed.
Through 2015, we identified 1,826 incident cases of invasive breast cancer, including 542 ER2 tumors and 1,015 ER1 tumors; information on ER status was not available for the remaining 269 cases. The distribution of ER status was similar to that reported elsewhere for AA women. 40 In addition, the distribution of breast cancer risk factors was similar in cases with known and unknown receptor status.
41,42
Exposure and covariate assessment
The baseline questionnaire collected information on established and putative risk factors for breast cancer including adult height, current weight, waist and hip circumferences, age at menarche, weight at age 18, oral contraceptive use, number and timing of births, breast cancer in first-degree relatives, menopausal status, age at menopause and use of menopausal female hormone supplements. Except for adult height, age at menarche and weight at age 18, all information was updated on follow-up questionnaires. Self-reports of weight and adult height were significantly correlated with technician measurements in a validation study. 43 Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters. Our main exposures of interest were adult height, age at menarche and age at attained height. On the 1999 questionnaire, women were asked the age at which they reached their full height, with response categories of "before age 13," "13-17 years of age," "after age 17" or "do not know." Age at attained height was unknown for 24% of women in the analytic cohort, many of whom had not completed the 1999 questionnaire.
Statistical analyses
For analyses of height and age at menarche, women contributed person-years from the beginning of follow-up in March 1995 until diagnosis of breast or other cancer, death, loss to follow-up, or end of follow-up in March 2015, whichever occurred first (1,046,258 total person-years). For analyses of age at attained height, we began follow-up in 1999 when this information was ascertained. We used Cox proportional hazards regression models, stratified by age in one-year intervals and questionnaire cycle such that age was the underlying time scale, to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for adult height, age at attained height, and age at menarche in relation to risk of overall, ER2, and ER1 breast cancer, separately. We considered each factor as a categorical variable and tested for linearity in associations of height and age at menarche by entering the continuous term of the variable in the models. We also evaluated associations of height and age at attained height within strata defined by age at menarche (11, 12-13 and 14 years) and height within strata of age at attained height (<13, 13-17 and >17 years). Multivariable models included mutual adjustment for the three factors of interest and for established breast cancer risk factors and potential confounders: first-degree family history of breast cancer, current BMI (continuous, kg/m 2 ), parity and age at first birth, oral contraceptive use, menopausal status and age at menopause, estrogen plus progestin use and education. Exposures and covariates were categorized as shown in Table 1 . Time-varying risk factors were updated at each questionnaire cycle. Missing indicator categories were used to account for missing information in covariates (generally 2-4%). A priori, we decided not to adjust for BMI at age 18, an established risk factor for breast cancer, 44 because it could be a mediator on the pathway between early growth and risk of breast cancer later in life. However, results were virtually unchanged in models that included BMI at age 18 (data not shown). There was no evidence of significant statistical interaction between BMI and menopausal status for risk of ER1 breast cancer in our multivariable models (p values 0.13); therefore, we did not retain interaction terms in our final multivariable models. Finally, to test whether associations differed by ER status, we used the contrast test method for heterogeneity by subtype. 45 All analyses were performed using SAS 9.3 (Cary, NC).
Results
Five percent of BWHS participants were 70 inches tall at maximum adult height; 17% were at least 68 inches tall. Among those with known age at attained height, the majority (74.5%) reported reaching their maximum height at ages 13-17; 7.7% percent reported reaching their adult height prior to age 13 and 17.8% reported reaching their adult height after age 17 . Approximately half of all women (52.2%) were 12-13 years old at the time of menarche; 28.8% were 11 years and 19.0% were 14 years. The distribution of other breast cancer risk factors at baseline is shown in Table 1 .
In mutually adjusted models, height was positively associated with breast cancer risk and both age at attained height and age at menarche were inversely associated with risk (Table 2) . Overall, the HR for women who were at least 70 inches tall relative to those who were 63 inches tall was 1.33 (95% CI: 1.08, 1.63; p value for linearity: 0.04). The observed positive association was restricted to ER1 breast cancer (HR: 1.44; 95% CI: 1.09, 1.89; p value for linearity: 0.04) with no statistically significant association observed for ER2 breast cancer (HR: 1.16; 95% CI: 0.78, 1.71; p value for linearity: 0.77); however, there was no evidence of statistical heterogeneity by subtype (p heterogeneity 5 0.34). Early age at attained height was associated with a 24% increase in risk of breast cancer overall, although not statistically significantly Adult height was associated with increased risk of ER1 breast cancer within each stratum of age at menarche, with the strongest association observed among women with menarche at ages 11 years (HR: 1.84; 95% CI: 1.14, 2.98). There was little evidence of a positive association of height with risk of ER2 breast cancer, except among women with menarche at ages 12-13 years (Table 3) . Similar patterns of associations were observed when analyses were stratified by age at attained height instead of age at menarche (Table 4) .
Age at menarche and age at attained height are moderately positively correlated (r 5 0.23), but it was still possible to examine the association of age at attained height with breast cancer risk within strata of age at menarche. The weak association of early age at attained height with increased risk of breast cancer was observed at each level of age at menarche, and for both ER1 and ER2 breast cancer, with nonstatistically significant HRs ranging from 1.15 to 1.35 (Table 5) .
Discussion
In this large prospective study of AA women, we found that being taller was associated with increased risk of ER1 breast cancer, but not ER2 breast cancer, regardless of age at attained height. There was a suggestion of an increased risk of both ER1 and ER2 breast cancer with younger age at attained height, independent of final attained height; however, the elevated HRs did not reach statistical significance. Our finding of a significant positive association between height and breast cancer risk is consistent with most of the current epidemiologic literature on this topic, 10 including our earlier report in the BWHS, 7 which was based on 674 prevalent and incident cases within the first 2 years of follow-up. Similar to others, 11, 46 we noted stronger associations of height with risk of ER1 than ER2 breast cancer. The consistently observed association between height and breast cancer risk may reflect hormonal influences during the pubertal growth spurt. In support of this hypothesis, earlier age at menarche is well-established risk factor for breast cancer, with risk increasing by about 5% for every year earlier at menarche, regardless of ER status. 5 In the current analysis, we also found that earlier age at attained adult height was associated with an increased risk of breast cancer, regardless of final height or age at menarche, albeit without statistical significance of the associations. Again, this finding is consistent with results from other studies. 12, 27, 33, 35, 36 In contrast to our observations for adult height, the magnitude of association for age at attained height and breast cancer risk was similar for both ER2 and ER1 breast cancer, corresponding to a 25-30% increased risk for women who reached their final adult height by age 13 compared to those who were >17 years old. Only one prior study considered the possibly differential association by ER status, noting a stronger association for ER2 breast cancer (HR: 1.9 for age at maximum height 12 years vs 17 years; 95% CI: 1.0, 3.9) than with ER1 breast cancer (HR: 1.2; 95% CI: 0.9, 1.7); however, that study included only 78 ER2 cases and there was not statistical heterogeneity. 12 It is difficult to disentangle the effects of early age at menarche from those of early age at attained height. Age at menarche is strongly correlated with breast development and also with age at attained height: on average, women reach their final adult height within 2 years of menarche. 32 While girls who go through menarche earlier tend to be taller than their peers during the pubertal years, 22, 28 the rapid skeletal growth that accompanies the pubertal growth spurt ends earlier, such that women with early menarche have shorter final adult heights. 5, 22, [29] [30] [31] We used age at attained height as a proxy for growth during childhood, as age at attained height is directly correlated with age at peak growth or the pubertal growth spurt, 32 and we controlled for age at menarche in multivariable models. The pubertal growth spurt is characterized by high concentrations of estrogens and IGF-1 and other growth hormones. [17] [18] [19] 25, 47 Li et al. hypothesized that earlier activation of the IGF-1/growth hormone pathway might increase breast cancer risk 27 ; later age at attained height could be protective because it reduces the duration of the susceptible period from menarche to terminal differentiation of breast tissue during first pregnancy. 33 Few previous studies have directly assessed growth velocity or timing of the pubertal growth spurt in relation to breast cancer risk. In a British cohort with available data on childhood anthropometric measures, DeStavola et al. 22 found that faster height velocities from ages 4 to 7 years and from ages 11 to 15 years were associated with 54% and 29% increased odds of breast cancer, respectively, and that these associations were especially strong among women with earlier ages at menarche. However, this study was limited by a small number of breast cancer cases (n 5 59). A derived measure of peak height velocity-estimated based on age at menarche, recalled body fatness at age 10 and final adult height-was also positively associated with breast cancer risk in the prospective Nurses' Health Study (n 5 806 premenopausal cases, 1,485 postmenopausal cases). 26 In contrast, in a Finnish record-linkage study, there was no apparent association between growth velocity as measured by change in Z score for height from ages 7 to 15 years and breast cancer risk; however, data on age at menarche were not available. 20 Finally, Bodicoat et al. 36 classified women as having had a growth spurt between ages 7 and 11 if their relative height compared to same-aged peers increased by at least one category, but found no association with breast cancer risk. Leg length has also been used as a proxy for exposures during the growth spurt, 48 because most of the growth during this period occurs in the long bones. 49 Studies have shown associations of both leg length and sitting height with breast cancer risk, 9, 11, 50 suggesting that both pubertal and prepubertal growth processes may influence future breast cancer risk.
Two previous studies considered a combination of age at menarche and height and showed a stronger association for breast cancer risk among women with both early menarche and tall stature. 11, 22 In the BWHS, we also found that the positive association between height and ER1 breast cancer was strongest among women who were 11 years old at menarche; however, taller height was an important risk factor for ER1 breast cancer regardless of age at menarche.
Some limitations of our analysis are worth noting. First, while current height was accurately reported, 43 there may have been inaccurate reporting of age at menarche and age at attained height, which were recalled many years after these events. However, any misclassification would be expected to be nondifferential with respect to breast cancer incidence. Second, we designed our question on age at attainment of height to have only three responses (<13, 13-17, later than 17) because our interest was in those with either early or late attainment; we did not expect participants to be able to characterize their age at adult height by exact year. In addition, we lacked information on age at attained height for nearly a quarter of our study population, those who did not complete the 1999 questionnaire or left that question blank, so statistical power was somewhat lower for these analyses. Finally, because all women in this study were AA, results may not be generalizable to other racial or ethnic groups.
The strengths of our study are considerable. With >1,100 breast cancer cases, the current analysis is the largest to date to investigate associations of age at attained height with breast cancer risk and the first among AA women, who have a high incidence of the most aggressive subtypes of breast cancer, including ER2 disease. Additionally, we were able to evaluate the association for both ER1 and ER2 breast cancer. Other strengths of this study include the prospective design and adjustment for established breast cancer risk factors that could act as confounders of the association.
In summary, results from this study add to the accumulating evidence that exposures during early life play an important role in breast cancer development later in life. While adult height, age at attained height and age at menarche are inter-related, our findings suggest that they may be independent risk factors for breast cancer. Moreover, observations that earlier age at menarche and earlier age at attained height are associated with risk of both ER2 and ER1 breast cancer-with similar magnitudes of association by ER statuswhile taller adult height is more strongly associated with ER1 than ER2 breast cancer, suggest that these factors may reflect distinct etiological pathways for breast carcinogenesis. Further research, especially in the context of large prospective studies, is warranted to elucidate these complex associations.
